Share on LinkedInShare on LinkedIn

ARTICLE · 04 APRIL 2024

The Interplay: Key Decisions At The Intersection Of Antitrust & Life Sciences - March 2024

WilmerHale
WilmerHale
Contributor
WilmerHale

WilmerHale

WilmerHale's London office was established more than 40 years ago. With lawyers qualified in the...

View firm profile
Explore more from WilmerHale

Calls for Removal of Device Patents Listed in the Orange Book Continue.

United StatesAntitrust/Competition Law

Calls for Removal of Device Patents Listed in the Orange Book Continue. FTC and Congressional action scrutinizing allegedly "improper" Orange Book listings continued apace in the first few months of 2024. In an earlier edition of The Interplay, we detailed the FTC's recent Policy Statement and its letters to ten pharmaceutical companies challenging over 100 patents that the FTC claimed were improperly listed in the Orange Book.

Following the FTC letters, on December 13, 2024, Senator Elizabeth Warren and Representative Pramila Jayapal wrote to eight pharmaceutical companies—AbbVie, Amneal, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline (GSK), Kaleo, Teva, and Viatris—asking whether they will de-list the patents the FTC claimed were improperly or inaccurately listed and to disclose whether they have taken action to enforce the patents. Similarly, on January 18, 2024, Senator Amy Klobuchar wrote six pharmaceutical companies—Abbvie, AstraZeneca,

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from